AGS Therapeutics

AGS Therapeutics is a preclinical-stage biotechnology company pioneering the use of Microalgae Extracellular Vesicles (MEVs) as a universal delivery system for innovative therapeutics, including mRNA, siRNA, DNA, proteins, and peptides. The company's technology leverages Chlorella, a freshwater microalga, to produce stable, biocompatible, and scalable delivery vehicles that can cross stringent biological barriers such as the blood-brain barrier and the intestinal epithelium. Headquartered in Paris at the Genopole biocluster, AGS operates with a subsidiary, AGS-M, which serves as a specialized CDMO for the production of MEV batches. The company aims to disrupt the delivery landscape by providing a non-viral, eco-friendly alternative to lipid nanoparticles (LNPs) and mammalian exosomes, with applications ranging from ophthalmology to oncology and vaccines.